Please login to the form below

Not currently logged in
Email:
Password:

Merck appoints new North America and China biopharma leaders

Gary Zieziula and Marc Horn take on new roles

Merck Gary ZieziulaGerman pharmaceutical company Merck has made two new appointments to its senior leadership team, promoting Gary Zieziula and Marc Horn.

Zieziula (pictured right) has been appointed president and managing director for Merck's North American biopharma, EMD Serono, replacing Paris Panayiotopoulos with immediate effect.

He will be responsible for the Massachusetts-based biopharma business' strategic direction and growth across the US and Canada. 

Zieziula brings over 30 years of pharmaceutical experience to the role, having held senior management positions at Amag Pharmaceuticals, Bristol Myers-Squibb, MSD and Roche, before joining Merck in 2015 as chief commercial officer for the US.

Meanwhile, Marc Horn will take on the role of managing director for Merck's biopharma business in China from 1 April.

Merck Marc HornBased in Beijing, Horn (pictured left) is currently chief financial officer overseeing Merck's healthcare, life science and performance materials sectors across Eastern Asia.

He has more than 16 years of financial experience in the industry and prior to joining Merck in 2014 as chief financial officer, Horn held management roles at Bayer and Lanxess.

Horn will report to Allan Gabor, Merck's current managing director for China, who has been promoted to president of the Asian-Pacific region for biopharma.

2nd February 2016

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Life Healthcare Communications

Life is a creative communications agency offering multi-channel solutions for the healthcare industry. We use a storytelling approach to turn...

Latest intelligence

Report: Customer experience, shaping digital healthcare
In this issue of ‘Perspective’ we speak with industry experts to learn about the world of digital healthcare, and how pharma is beginning to utilise these modern technologies to enhance...
Biomarker
Encouraging signs in biomarker R&D
The cancer immunotherapy firms ramping-up biomarker R&D...
Programmatic methodology and why you should be using it
What is it? How does it work? Why is everyone talking about it? By Richard Webb - Associate Director...

Infographics